Clinical Trial: Phase 1 Study of HS-20093 Combinations in Patients With Extensive Stage Small Cell Lung Cancer

U.S., July 15 -- ClinicalTrials.gov registry received information related to the study (NCT07063407) titled 'Phase 1 Study of HS-20093 Combinations in Patients With Extensive Stage Small Cell Lung Cancer' on July 03.

Brief Summary: This is a Phase I clinical study of HS-20093. The purpose of this study is to evaluate the safety, tolerability, PK and efficacy of HS-20093 in combination with Adebrelimab in patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC).

Study Start Date: July 31

Study Type: INTERVENTIONAL

Condition: Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Intervention: DRUG: HS-20093 in combination with Adebrelimab

HS-20093 in combination with Adebrelimab will be administered intravenously every 3 weeks until ...